AzTrials
AzTrials

Spinal NeoplasmsNCT04192383

Evaluation of Effectiveness of CyberKnife Stereotactic Radiosurgery for Spinal Tumors

An observational study of Spinal Neoplasms, run by Peking University Third Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study aims to explore the reliability of the combination of functional magnetic resonance imaging and radiomics for evaluation of the therapeutic efficacy of CyberKnife stereotactic radiosurgery for spinal tumors. Read more about this study

Who is it for?
Any age
Conditions the study is for
Spinal Neoplasms
What is being tested?
Cyberknife stereotactic radiosurgery
Type of treatment
Surgery or procedure
How many people
60 participants
Where
1 siteChina
Study dates
1 Sep 2018to 1 Jan 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Cohorts will be selected form Peking University Third Hospital.

Who may be able to join

  • Biopsy-proven spinal or paraspinal metastases;
  • MRI and DCE-MRI examination performed before and at 3 months after CyberKnife treatment.

Who cannot join

  • Area of the lesion surgically removed before enrollment;
  • Prior percutaneous vertebroplasty or kyphoplasty or radiation therapy of the target lesion;
  • Chemotherapy within a month;
  • Unable to cooperate with-or refusal of-CT, conventional MRI, or DCE-MRI examination;
  • Lost to follow-up;
  • Poor image quality that cannot be analyzed.

Trial locations and contacts

1 site in 1 country.

China1 site, 1 recruiting
  • Yongye Chen

    Beijing, Beijing Municipality

    Yongye Chen, MS, 13426194125 ext. 13426194125, chenyongye1995@163.com

    Recruiting

Other trials in China

About this study

Official title: Functional Magnetic Resonance Imaging Combined With Radiomics for Evaluation of Effectiveness of CyberKnife Stereotactic Radiosurgery for Spinal Tumors

This study aims to explore the reliability of the combination of functional magnetic resonance imaging and radiomics for evaluation of the therapeutic efficacy of CyberKnife stereotactic radiosurgery for spinal tumors. Accurate imaging assessment can help clinicians plan personalized therapeutic schedules for patients with spinal tumors .

Read the detailed description

Spinal tumors may be metastases or primary tumors; the former are more common. About 40% of cancer patients will have spinal metastasis. Primary spinal tumor is relatively rare, accounting for only about 8% of spinal tumors. For both metastasis and primary tumor, the aim of treatment is to reduce pain, maintain or improve neurological function, and maintain or restore spinal stability.

In patients who cannot undergo surgery or need additional treatment after surgery, radiation therapy can relieve pain, prolong survival, improve the success rate of surgery, and reduce risk of metastasis and recurrence. However, the complex anatomy of the spine, and the numerous important organs around it, makes radiation treatment challenging. High-dose radiation therapy is necessary for long-term control of the tumor and for prevention of spinal column instability; however, this is impossible with traditional radiotherapy due to the presence of the radiosensitive spinal cord. Outcomes therefore tend to be poor for large and complex lesions. The CyberKnife-a stereotactic body radiation therapy (SBRT) platform that combines a lightweight linear accelerator, a robotic arm, an imaging system, and a respiratory tracking system-offers a feasible approach. It can achieve submillimeter level-precision treatment under imaging guidance.

Currently, the effectiveness of CyberKnife radiosurgery for spinal tumors is decided by assessing imaging changes, relief of clinical symptoms, and needle biopsy, but all of these methods have limitations. On imaging, for example, change in lesion volume is used to assess tumor regression, but the size of a spinal tumor is not easy to measure and, moreover, decrease in tumor volume after treatment may take time . Post-treatment signal intensity changes in conventional magnetic resonance imaging (MRI) T1-weighted and T2-weighted sequences are difficult to interpret, and their relationship with treatment efficacy is also not clear.

Generally speaking, alterations in microscopic structure and biological activity of the tumor occur much earlier than changes in gross morphology . Functional magnetic resonance imaging (fMRI) can therefore be more useful than conventional MRI for assessing treatment response. In fMRI, sequences such as diffusion-weighted imaging (DWI), dynamic contrast-enhanced MRI (DCE-MRI), and diffusion kurtosis imaging (DKI) reflect functional information of tissues from different perspectives.

Application of artificial intelligence technology for analysis of medical imaging data is now an area of intense research. This new method, which is called radiomics, can help in solving many difficult clinical problems. By extracting a large number of highly representative quantitative imaging features from high-throughput medical image data, radiomics can help in evaluating treatment efficacy and predicting prognosis of spinal tumors.

Investigators intend to explore the use of the combination of fMRI and radiomics for evaluating the effectiveness of CyberKnife radiosurgery for spinal tumors. The method will be able to evaluate both volume and functional changes in the tumor, and thus provide important information for planning of individualized therapeutic schedules for patients with spinal tumors.

Being tested
Cyberknife stereotactic radiosurgery
Keywords
Spinal Neoplasms, Stereotactic Body Radiotherapy, CyberKnife Radiosurgery, Functional MRI, treatment outcome
Medical subject headings
Spinal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cyberknife stereotactic radiosurgeryRadiation

    Hypofractionated stereotactic radiosurgery

Study groups in NCT04192383
Study groupRoleWhat they receive
CyberknifeNot described
Receives: Radiation: Cyberknife stereotactic radiosurgery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Overall survival(OS)

    The time from the start of treatment to the date of death or last follow-up

    Measured: From the start of randomization to the date of death of the patient or the end of the study (at 60 months).

Secondary outcomes (3)
  1. Progression-free survival(PFS)

    The time from the start of treatment to the date of diagnosis of tumor progression or death. Tumor progression is defined as increase in lesion volume on MRI compared to baseline, or identification of new metastasis on imaging or histological examination.

    Measured: From the start of randomization to the first evidence of tumor progression or death of the patient or the end of the study (at 60 months), whichever occurs first.

  2. Numerical rating scales (NRS)

    A 11 point scale where the end points are the extremes of no pain and pain as bad as it could be, or worst pain.

    Measured: Measurements will be performed every 3 months, starting from randomization until the patient's death or till end of the study (at 60 months ).

  3. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    The QLQ-C30 is a cancer-specific, self-administered, structured questionnaire designed for use in clinical trials, which contains 30 questions (items),

    Measured: Measurements will be performed every 3 months, starting from randomization until the patient's death or till end of the study (at 60 months ).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Dec 2019
  2. Study start1 Sep 2018
  3. Primary completion1 Jun 2021
  4. Study completion1 Jan 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
60 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04192383
Sponsor's protocol ID
IRB00006761-M2018251
Status last verified
Feb 2021
First submitted
5 Dec 2019
Last updated
29 Jun 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Spinal Neoplasms, run by Peking University Third Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Overall survival(OS) (time frame: From the start of randomization to the date of death of the patient or the end of the study (at 60 months).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in